Kristen Brantley

Dr. Kristen Brantley

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Cancer Epidemiology
Verified
Journal Article
Closed access
KBKristen Brantley
Kristen Brantley
ARAnders H. Riis
Anders H. Riis
RERune Erichsen
Rune Erichsen
OTOle Thorlacius-Ussing
Ole Thorlacius-Ussing
HMHolger Jon Møller
Holger Jon Møller
TLTimothy L. Lash
Timothy L. Lash

31 May 2018 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
KBKristen Brantley
Kristen Brantley
AKAnders Kjærsgaard
Anders Kjærsgaard
DCDeirdre Cronin-Fenton
Deirdre Cronin-Fenton
RYRami Yacoub
Rami Yacoub
ANAnja S. Nielsen
Anja S. Nielsen
TLTimothy L. Lash
Timothy L. Lash
Background: Expression of human paracrine hormones stanniocalcin 1 (STC1) and stanniocalcin 2 (STC2) may potentiate late breast cancer recurrence. We tested the hypothesis that expression of STC1 and STC2 in primary breast tumors is more strongly associated with late versus early recurrences. Methods: A total of 541 estrogen receptor–positive, tamoxifen-treated (ER+/TAM+) and 300 ER-negative, tamoxifen-untreated (ER−/TAM−) breast cancer patients who experienced recurrence within 10 years of primary diagnosis and matched recurrence-free controls were selected from a cohort of 11,251 Danish breast cancer patients diagnosed with stage I, II, or III breast cancer during 1985 to 2001. The association between IHC expression of STC1 and STC2 in primary breast tumor tissue microarrays and breast cancer recurrence was evaluated within median time to recurrence quintiles. Results: The association between STC1 expression, dichotomized as positive or negative, and recurrence was strongly positive for the final time quintile (6–10 years postdiagnosis) in the ER+/TAM+ group [aOR = 2.70; 95% confidence interval (CI): 1.22–5.98]. Regression of the log ORs relating dichotomous STC1 and STC2 expression to recurrence by median time to recurrence (year) resulted in a relatively large positive effect estimate for STC1 (β = 0.16; 95% CI, −0.03–0.36) and a near-null positive effect estimate for STC2 (β = 0.04; 95% CI, −0.14–0.21). Conclusions: Our results suggest a stronger association between primary tumor STC1 expression and late recurrence, as opposed to early recurrence, although no clear trend was apparent. Impact: STC1 expression in the primary tumor may potentiate late recurrences, suggesting dormancy pathways that merit further investigation. Cancer Epidemiol Biomarkers Prev; 27(6); 653–9. ©2018 AACR.

21 May 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
ERErika Rees-Punia
Erika Rees-Punia
LTLauren Teras
Lauren Teras
CNChristina C Newton
Christina C Newton
SMSteven Moore
Steven Moore
ILI-Min Lee
I-Min Lee
APAlpa V Patel
Alpa V Patel
Background: Evidence for potential mortality benefits of leisure-time moderate-to-vigorous intensity physical activity (MVPA) for survivors of cancer types beyond breast and colorectal is limited. The aim of this study was to evaluate relationships between postdiagnosis MVPA and all-cause mortality in participants with a history of 11 cancer types. Methods: Data were pooled from 6 United States–based cohort studies. Cohort-specific hazard ratios (HRs) and 95% confidence intervals (CIs) for associations of MVPA assessed ≥1 year after a cancer diagnosis and all-cause mortality were calculated using multivariable Cox proportional hazards models and then pooled using random effects meta-analysis. Models were adjusted for age, sex, race/ethnicity, smoking status, alcohol use, and cancer treatment and stage. The sample included 90 844 cancer survivors (mean [standard deviation] age at diagnosis = 67 [10] years, 55% women), among whom 45 477 died during 10.9 [7.0] years of follow-up. Results: Compared with no MVPA, engaging in recommended amounts of MVPA (7.5 to <15 MET-hr/wk) was related to better overall survival in participants with a history of 1 of 10 cancer types: oral (HR = 0.44, 95% CI = 0.27 to 0.73), endometrial (0.50, 95% CI = 0.34 to 0.76), lung (0.51, 95% CI = 0.38 to 0.68), rectal (0.51, 95% CI = 0.36 to 0.71), respiratory (0.51, 95% CI = 0.29 to 0.72), bladder (0.53, 95% CI = 0.40 to 0.72), kidney (0.53, 95% CI = 0.37 to 0.77), prostate (0.60,95% CI = 0.49 to 0.74), colon (0.61, 95% CI = 0.50 to 0.76), and breast (0.67, 95% CI = 0.55 to 0.81). Eight of the 10 observed inverse associations remained similar when excluding participants who died within 2 years of follow-up. Conclusion: Engaging in leisure-time MVPA after a cancer diagnosis appears to improve survival for people with a history of several cancer types, including bladder, breast, colon, endometrial, kidney, lung, oral, prostate, rectal, and respiratory cancer.

21 January 2022 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
KBKristen Brantley
Kristen Brantley
OZOana Alina Zeleznik
Oana Alina Zeleznik
BRBernard Rosner
Bernard Rosner
RTRulla M. Tamimi
Rulla M. Tamimi
JAJulian Avila-Pacheco
Julian Avila-Pacheco
HEHeather Eliassen
Heather Eliassen
Background: Metabolite profiles provide insight into biologic mechanisms contributing to breast cancer development. We explored the association between prediagnostic plasma metabolites (N = 307) and invasive breast cancer among postmenopausal women in a nested case–control study within the Nurses' Health Study (N = 1,531 matched pairs). Methods: Plasma metabolites were profiled via LC/MS-MS using samples taken ≥10 years (distant, N = 939 cases) and <10 years (proximate, N = 592 cases) before diagnosis. Multivariable conditional logistic regression was used to estimate ORs and 95% confidence intervals (CI) comparing the 90th to 10th percentile of individual metabolite level, using the number of effective tests (NEF) to account for testing multiple correlated hypotheses. Associations of metabolite groups with breast cancer were evaluated using metabolite set enrichment analysis (MSEA) and weighted gene coexpression network analysis (WGCNA), with adjustment for the FDR. Results: No individual metabolites were significantly associated with breast cancer risk. MSEA showed negative enrichment of cholesteryl esters at the distant timepoint [normalized enrichment score (NES) = −2.26; Padj = 0.02]. Positive enrichment of triacylglycerols (TAG) with <3 double bonds was observed at both timepoints. TAGs with ≥3 double bonds were inversely associated with breast cancer at the proximate timepoint (NES = −2.91, Padj = 0.03). Conclusions: Cholesteryl esters measured earlier in disease etiology were inversely associated with breast cancer. TAGs with many double bonds measured closer to diagnosis were inversely associated with breast cancer risk. Impact: The discovered associations between metabolite subclasses and breast cancer risk can expand our understanding of biochemical processes involved in cancer etiology.

30 October 2018 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
KBKristen Brantley
Kristen Brantley
TDTeresa D Douglas
Teresa D Douglas
RSRani H. Singh
Rani H. Singh
People with Phenylketonuria (PKU) who respond to tetrahydrobiopterin (BH4) often decrease dependence on medical food (MF) following increased phenylalanine (phe) tolerance. Responders to BH4 may experience a reduction in certain nutrients if not compensated through intact foods or supplements. This study investigated B6, B12, folate, and iron status based on blood levels and dietary intake in patients with PKU responsive to BH4 over 1 year. Fifty-eight patients with PKU, ages 4–50 years were recruited and initiated on BH4 therapy. Patients were monitored for BH4 response, and nutritional status was recorded at regular intervals over 12 months. The analysis included 33 patients with known BH4 response status and complete nutritional data. Nutrient intake was determined by National Data System for Research (NDSR) analysis of self reported 3 day diet records and compared to Dietary Reference Intakes (DRIs). Blood biomarkers were analyzed by Quest Diagnostics and compared to laboratory reference ranges. Patient laboratory values were compared to controls from the National Health and Examination Survey (NHANES). Differences in nutrient intakes across time points were examined, stratified by age, using nonparametric methods. Statistical analyses were completed with SAS 9.4, with significance set at α = 0.05. Medical food intake declined among pediatric (p < 0.01) and adult (p = 0.06) BH4 responders over 1 year. Among those < 18 years of age, mean percent of calories obtained from MF declined from 21.3 to 4.7%. In adults, percent calories from MF dropped from 19.5 to 4.0%. Though maintaining laboratory and dietary values within reference ranges, responders < 18 years experienced a significant decline in serum B12 (p = 0.01), dietary folate (p = 0.006), and dietary iron (p = 0.004) over the study. Although mean dietary and laboratory values for B12, B6, folate, and iron in BH4 responders and non-responders were adequate at baseline and 12-month follow-up, responders experienced a significant decline in serum B12 over 1 year, which may be explained by decreased intake of fortified MF. Both response groups had lower serum B12 than NHANES controls at baseline and 12 months. Results indicate a need to monitor B12 concentrations and consider micronutrient supplementation, with special attention to pediatric patients with PKU.

25 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
MZMaria Zanti
Maria Zanti
DODenise G. O’mAhony
Denise G. O’mAhony
MPMichael T. Parsons
Michael T. Parsons
LDLeila Dorling
Leila Dorling
JDJoe Dennis
Joe Dennis
KMKyriaki Michailidou
Kyriaki Michailidou
Clinical genetic testing identifies variants causal for hereditary cancer, information that is used for risk assessment and clinical management. Unfortunately, some variants identified are of uncertain clinical significance (VUS), complicating patient management. Case-control data is one evidence type used to classify VUS. As an initiative of the Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Analytical Working Group we analyze germline sequencing data of BRCA1 and BRCA2 from 96,691 female breast cancer cases and 302,116 controls from three studies: the BRIDGES study of the Breast Cancer Association Consortium, the Cancer Risk Estimates Related to Susceptibility consortium, and the UK Biobank. We observe 11,207 BRCA1 and BRCA2 variants, with 6909 being coding, covering 23.4% of BRCA1 and BRCA2 VUS in ClinVar and 19.2% of ClinVar curated (likely) benign or pathogenic variants. Case-control likelihood ratio (ccLR) evidence is highly consistent with ClinVar assertions for (likely) benign or pathogenic variants; exhibiting 99.1% sensitivity and 95.3% specificity for BRCA1 and 93.3% sensitivity and 86.6% specificity for BRCA2. This approach provides case-control evidence for 787 unclassified variants; these include 579 with strong or moderate benign evidence and 10 with strong pathogenic evidence for which ccLR evidence is sufficient to alter clinical classification.